Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.
Tendai Mugwagwa, José Marcano Belisario, Louise Hartley et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic literature review evaluated the economic and health-related outcomes of nirmatrelvir/ritonavir (NMV/r) treatment for mild to moderate COVID-19 in high-risk patients. The review included 33 economic evaluations, revealing that NMV/r treatment is associated with reduced hospitalizations and deaths, as well as increased quality-adjusted life-years (QALYs).
Key findings
- NMV/r treatment was linked to a reduction in hospitalizations and deaths.
- Eighteen studies reported an increase in quality-adjusted life-years (QALYs) with NMV/r treatment.
- The treatment was associated with fewer patients experiencing long COVID complications.
Why it matters
Understanding the economic and health-related benefits of NMV/r treatment can inform clinical decision-making and resource allocation, particularly in managing COVID-19 in high-risk populations.
What to keep in mind
Most studies were conducted in high-income countries and had limited data on the long COVID population.